91 215

Cited 0 times in

Body mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial

DC Field Value Language
dc.contributor.author고영국-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author신동호-
dc.contributor.author안철민-
dc.contributor.author이승준-
dc.contributor.author이용준-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author홍성진-
dc.date.accessioned2023-07-12T02:33:42Z-
dc.date.available2023-07-12T02:33:42Z-
dc.date.issued2023-03-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/195342-
dc.description.abstractBackground: Although ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT) results in a significantly greater net clinical benefit over that with ticagrelor-based 12-month DAPT in patients with acute coronary syndrome (ACS), it remains uncertain whether this effect is dependent on body mass index (BMI). We aimed to evaluate the BMI-dependent effect of these treatment strategies on clinical outcomes. Methods: This was a pre-specified subgroup analysis from the TICO trial (Ticagrelor Monotherapy After 3 Months in Patients Treated With New Generation Sirolimus-eluting Stent for Acute Coronary Syndrome), evaluating the interaction between BMI and treatment strategies for the primary outcome [composite of major bleeding and adverse cardiac and cerebrovascular events (MACCE): death, myocardial infarction, stent thrombosis, stroke, or target-vessel revascularization]. The secondary outcomes were major bleeding and MACCE. Results: Based on a pre-specified BMI threshold of 25 kg/m2, 3,056 patients were stratified. Patients with BMI <25 kg/m2 had a higher risk of primary and secondary outcomes than those with BMI ≥25 kg/m2. Regardless of the BMI subgroup, the effects of ticagrelor monotherapy after 3-month DAPT on the primary outcome (p int = 0.61), major bleeding (p int = 0.76), and MACCE (p int = 0.80) were consistent without significant interaction compared with ticagrelor-based 12-month DAPT. The treatment effects according to the BMI quartiles and age, sex, and diabetic status were also consistent without significant interaction. Conclusion: The BMI-dependent impact of ticagrelor monotherapy after 3-month DAPT compared with 12-month DAPT on clinical outcomes was not heterogeneous in patients with ACS. Clinical trial registration: [www.ClinicalTrials.gov], identifier [NCT02494897].-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherFrontiers Media S.A.-
dc.relation.isPartOfFRONTIERS IN CARDIOVASCULAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleBody mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorByung Gyu Kim-
dc.contributor.googleauthorSung-Jin Hong-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorYong-Joon Lee-
dc.contributor.googleauthorSeung-Jun Lee-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorDong-Ho Shin-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.3389/fcvm.2023.1128834-
dc.contributor.localIdA00127-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA02097-
dc.contributor.localIdA02269-
dc.contributor.localIdA02927-
dc.contributor.localIdA02984-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA04403-
dc.relation.journalcodeJ04002-
dc.identifier.eissn2297-055X-
dc.identifier.pmid37063970-
dc.subject.keywordacute coronary sydrome-
dc.subject.keywordbody mass index-
dc.subject.keyworddrug eluting stent-
dc.subject.keyworddual antiplatelet therapy-
dc.subject.keywordticagrelor-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor신동호-
dc.contributor.affiliatedAuthor안철민-
dc.contributor.affiliatedAuthor이승준-
dc.contributor.affiliatedAuthor이용준-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍성진-
dc.citation.volume10-
dc.citation.startPage1128834-
dc.identifier.bibliographicCitationFRONTIERS IN CARDIOVASCULAR MEDICINE, Vol.10 : 1128834, 2023-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.